BACHEM HOLDING increases its risk exposure and slightly lowers to Neutral
BACHEM HOLDING (CH), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date September 28, 2021, the closing price was CHF 697.00 and its expected value was estimated at CHF 680.37.Bachem Holding is a technology-based company specializing in the development of manufacturing processes for the production of biochemical and pharmaceutical compounds for the pharma and biotech industries, as well as the development of manufacturing processes. Co. specializes in process development and manufacturing of peptides and complex organic active pharmaceutical ingredients and biochemicals for research purposes. In the field of generics, Co. offers both peptides used for the manufacture of pharmaceuticals as well as organic active ingredients that have run out of patent. Co.'s range of research ingredients covers the catalog business as well as custom synthesis.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.